Information Provided By:
Fly News Breaks for November 4, 2019
Nov 4, 2019 | 07:36 EDT
JPMorgan analyst Cory Kasimov initiated coverage of BioNTech with an Overweight rating and $23 price target. The company is taking an immuno-oncology approach to attack cancer and using multiple tools to address the heterogeneous nature of tumor biology, Kasimov tells investors in a research note. He sees a "well-defined catalyst calendar" with BioNTech having at least five programs reading out over the course of 2020.